Press release
PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024
SEONGNAM, South Korea - PharmaResearch, a leading pharmaceutical/medical device research company, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, scheduled from April 5th to 10th in San Diego, California. The company will unveil research findings regarding its groundbreaking anticancer agent, PRD-101, through a poster session.
The presentations will cover diverse topics, including the efficacy demonstrated in various patient-derived xenograft (PDX) animal models and the results of in-depth characterization conducted by the National Cancer Institute's Nanotechnology Characterization Laboratory (NCL).
Presentation Details
Poster Title: Efficient and safe delivery of doxorubicin by DNA fragments: A full preclinical study Date and Time: Tuesday April 9, 1:30 AM - 5:00 PM PT
Session Category: Chemistry
Session Title: Drug Delivery
Session Location: Section 20
Poster Board Number: 3
Abstract number: 5735
About PharmaResearch's PRD-101
PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimization technology (DOTTM) in nano-particle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive license associated with PRD-101, marking a milestone in the company's innovative endeavors.
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy. The company is committed to advancing quickly into clinical trials based on promising safety and efficacy results obtained from preclinical studies.
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. With a diverse portfolio encompassing medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients, DOTTM PDRN and DOTTM PN. These active tissue regenerative substances are powered by DOTTM, an exclusive DNA fragments optimization technology safeguarded by a suite of patents. PharmaResearch is located in Seongnam, South Korea, and its US subsidiary, PharmaResarch USA is located in Costa Mesa, Califrornia, US.
PharmaResearch's participation in the AACR Annual Meeting underscores its dedication to pioneering advancements in cancer research and treatment, ultimately aiming to improve patient outcomes and quality of life.
For more information about PharmaResearch and its innovative initiatives, visit http://pharmaresearch.co.kr/en
Media Contact
Company Name: PharmaResearch USA.
Contact Person: Sangjin Choi
Email: Send Email [http://www.universalpressrelease.com/?pr=pharmaresearch-to-present-the-research-on-its-nano-anticancer-drug-prd101-at-the-aacr-annual-meeting-2024]
Country: United States
Website: http://pharmaresearch.co.kr/en/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024 here
News-ID: 3444393 • Views: …
More Releases from Getnews
Matthew West-James' new Non-Fiction book receives a warm literary welcome
Image: https://www.globalnewslines.com/uploads/2026/07/1783709557.jpg
Readers' Favorite announces the review of the Non-Fiction - Military book "Kevlar, Tattoos and Invisible Scars" by Matthew West-James, currently available at http://www.amazon.com/gp/product/B0GX9YQ5YH.
Readers' Favorite is one of the largest book review and award contest sites on the Internet. They have earned the respect of renowned publishers like Random House, Simon & Schuster, and Harper Collins, and have received the "Best Websites for Authors" and "Honoring Excellence" awards from the…
Book Publicity Pro Scott Lorenz and Media Expert Jess Todtfeld Reveal How Author …
New Success in Media articles share insider strategies for securing publicity, delivering memorable interviews, and building a successful author platform.
New York, NY, USA - July 10, 2026 - Two leading experts in media visibility and author promotion are sharing their playbooks for success. Media trainer Jess Todtfeld and veteran book publicist Scott Lorenz, President of Westwind Book Marketing [https://www.westwindbookmarketing.com/], are featured in recent Success in Media [https://www.successinmedia.com/] articles that show…
New Study of 56,606 Press Releases Reveals the Best Day and Time to Send One, an …
Image: https://www.globalnewslines.com/uploads/2026/07/1783714629.jpg
Share of press releases by day of week and hour of day, from a 2026 PR Gun study of 56,606 press releases across ten major newswire services.
PR distribution platform PR Gun analyzed 56,606 press releases sent across ten major newswires in 2026. The data shows Thursday is the busiest day (22.6%), noon the busiest hour (13.9%), the average release runs 870 words, nearly 1 in 5 calls something "innovative,"…
World Cup 2026 Semi-Finals: The Eight Contenders and Their Chances
With the quarter-finals underway, the 2026 FIFA World Cup has been trimmed to its final eight. All three co-hosts are already out, along with traditional powerhouses like Brazil and Germany, leaving reigning champions Argentina, plus Belgium, England, France, Morocco, Norway, Spain, and Switzerland to fight for a place in the semi-finals - and, ultimately, the final at MetLife Stadium.
France
France head into the quarter-finals as the tournament's form team, having outscored…
More Releases for PharmaResearch
PharmaResearch Hosts 5th Global Symposium on 'Rejuran'
Over 600 Medical Professionals from 25 Countries Participate, Launch of IRC Committee for Rejuran Global Research Team
Image: https://www.getnews.info/uploads/184db9fd8e5f5bcffadcfd0b82962264.png
Seongnam, South Korea - PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it successfully held the 5th PharmaResearch Global Symposium (PGS) at the Lakai Sandpine Resort on October 28-29, 2024. This year's event attracted approximately 600 aesthetic and medical professionals from 25 countries across Asia, the Americas, Europe, and the…
PharmaResearch Accelerates Global Market Expansion with Investment from Global P …
Accelerating Overseas Expansion and Market Strengthening through CVC Partnership, M&As, and R&D Investments
Image: https://www.getnews.info/uploads/37d3d1ec3a03e85dac6376b2c2e3bb4e.jpg
September 13th, 2024 - PharmaResearch (co-CEOs: Kang Ki Seock, Kim Thinkyou), a leader in aesthetic injectables and regenerative medicines renowned for its flagship skin booster product "Rejuran", announced a significant milestone in its global market expansion efforts, securing KRW 200 billion investment from Europe-based global private equity firm CVC through the issuance of redeemable convertible preferred shares…
PharmaResearch Announces 'Open Innovation Day' Running Until September 30 to Fos …
Anticipating Collaborations with Leading Companies in Aesthetic Medical Devices, Pharmaceuticals and Biotechnology: Application Period August 15 - September 30
Image: https://www.getnews.info/uploads/3276751a42ffba8429fb959e81d25795.jpg
PharmaResearch, a company specializing in regenerative medicine (CEO Kim Thinkyou, Kang Ki-seock), announced that it will host the 'Open Innovation Day'. This initiative aims to foster collaborations in innovative technologies across the aesthetic medical device, pharmaceuticals, biotechnology sectors, both domestically and internationally.
PharmaResearch is seeking partnerships in several key areas, including -…
PharmaResearch Hosts Launch Symposium for REJURAN Registered HB Plus in Singapor …
Sharing information on DOT Trademark patented technology, distinctive efficacy, and safety
Image: https://www.getnews.info/uploads/a9dbc52352e6614785a6dbafd0148817.png
PharmaResearch (CEOs Kang Ki-seok and Kim Thinkyou), a company specializing in regenerative medicine, announced earlier this month that it held a launch symposium for REJURAN Registered HB Plus at Four Seasons Hotel in Singapore.
The symposium aimed to share the technological advancements and clinical experiences of REJURAN Registered HB Plus with local aesthetic experts and medical professionals.
Dr. Michael J. Kim,…
Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) Market Trends, Key Benefi …
Los Angeles, USA: QY Research has recently unveiled a comprehensive report titled, "Global Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) Market Report: Insights, Forecast to 2030." This detailed analysis examines the multiple elements shaping the future of the global Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) market.
The Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) report serves as an invaluable resource for industry players, providing precise and extensive research insights necessary for strategic decision-making. The analysts have…
PharmaResearch Presents 'REJURAN Registered ' as a New Solution for Flushing
Effective Use of PN for Flushing... Published in an SCIE-Level Journal
Image: https://www.getnews.info/uploads/52b03d248c2ca7ae3fdd1f69ef67ba5c.png
Flushing refers to the temporary or persistent redness of the skin on the face and neck. It occurs due to vasodilation and is known to arise from various causes, such as hormonal changes, sudden temperature fluctuations, inflammatory skin diseases, and prolonged laser treatments.
While laser and hormone therapies are common treatments for flushing, PharmaResearch(CEO Kim Thinkyou, Kang Ki-seok) has recently…
